top of page

3Biotech x Acticor Biotech



Who is Acticor Biotech?

Founded in 2013, Acticor Biotech is currently conducting two phase 2/3 clinical studies. The development of our monoclonal antibody fragment, glenzocimab, for stroke treatment has been particularly rapid.

Why did you call on 3Biotech?

We began focusing on Chemistry Manufacturing and Control (CMC) very early on. One year after the creation of Acticor Biotech, the sequence of our monoclonal antibody fragment (ACT017) had just been humanised and we had to choose a bio-production system.

In order to accomplish this, we needed expertise that we did not have in-house. We worked with 3Biotech to define what patients, clinicians, and regulatory agencies would require of our drug candidate. From there, the Target Product Profile and the timeline were built. 3Biotech helped us find the right production system, define the formulation and target stability, select the right CDMO provider and coordinate and facilitate the relationship with the CDMO.

Our antithrombotic Fab has successfully passed the various stages of development. In September 2021, we enrolled our first patient in ACTISAVE, an adaptive Phase 2/3 study in stroke, and last November, Acticor biotech was granted an IND to conduct this Phase 2/3 in the US. The early implementation of a CMC strategy has clearly contributed to our rapid development, without any backtracking.




bottom of page